Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01229228 · ClinicalTrials.gov registry record · Phase 2

Study of Naproxen Capsules to Treat Dental Pain

A Phase 2 study, sponsored by Iroko Pharmaceuticals.

Completed
Registry status
Phase 2
Development phase
254
Enrollment target

NCT01229228 is a Phase 2 study that has completed, run by Iroko Pharmaceuticals. The registered enrollment target is 254 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01229228, a Phase 2 study, has completed, sponsored by Iroko Pharmaceuticals.

COMPLETED
Registry status
Phase 2
Development phase
254 participants
Enrollment target

Study Summary

The purpose of the study is to determine whether Naproxen Test Formulation Capsules are safe and effective for the treatment of dental pain.

Interventions

  • DRUG Placebo
  • DRUG Naproxen Test
  • DRUG Naprosyn

Trial Details

FieldValue
Enrollment Target 254 participants
Start Date 2010-10
Est. Completion 2011-04
Phase Phase 2

Sponsor

Iroko Pharmaceuticals

12 total trials

What the Registry Record Tells You About NCT01229228

The ClinicalTrials.gov registry entry for NCT01229228 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 254 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Iroko Pharmaceuticals, which has 12 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.

NCT01229228 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT01229228 about?

NCT01229228 is a clinical study titled "Study of Naproxen Capsules to Treat Dental Pain". The purpose of the study is to determine whether Naproxen Test Formulation Capsules are safe and effective for the treatment of dental pain.

What is the current status of trial NCT01229228?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 254 participants. The study started on 2010-10. Estimated completion is 2011-04.

What interventions are being tested in trial NCT01229228?

The interventions under investigation include: Placebo (DRUG), Naproxen Test (DRUG), Naprosyn (DRUG).

Who is sponsoring clinical trial NCT01229228?

This trial is sponsored by Iroko Pharmaceuticals, which has 12 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.